- Shares of TrovaGene (TROV -12.7%) have moved steadily lower throughout the session and are now down double-digits on twice their average 10-day volume.
- Perhaps weighing on sentiment is an ostensibly bullish article from SA contributor Douglas House which, upon a closer read, has some rather disconcerting things to say about the company's prospects.
- House flags "nosebleed" numbers for price/ book, revenue/ share, price/ to sales, and revenue/ employee and characterizes the status of TrNA testing as "embryonic."
- After a lengthy review, the author does note several "TROV-specific events [that should] bolster the company's prospects over the next 1-2 years," but it's probably the last paragraph that comes across the most bearish: "This stock is not for buy-and-hold types because of its speculative nature [and] if you hold onto your position expecting to see ... the company blossoming into the next Celgene, it ain't going to happen."
TrovaGene slides, article explores company's potential
Aug 30 2013, 14:32 ET